Overview

Study of Telitacicept in Generalized Myasthenia Gravis

Status:
Not yet recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in the treatment of patients with generalized myasthenia gravis.
Phase:
Phase 3
Details
Lead Sponsor:
RemeGen Co., Ltd.